Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Fletcher

Showing results (141-150 of 205) with videos related to

Pageof 21
Sort By:
The American Journal of Surgical Pathology|March 30, 2012
The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumorCheng-Han Lee, Adrian Mariño-Enriquez, Wenbin Ou, et al.
British Journal of Cancer|May 4, 2016
Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapyMarieke A de Graaff, Marije A J de Rooij, Brendy E W M van den Akker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)Michael C Heinrich, Grant A McArthur, George D Demetri, et al.
Clinical Sarcoma Research|March 15, 2019
Genomic aberrations in cell cycle genes predict progression of <i>KIT</i>-mutant gastrointestinal stromal tumors (GISTs)Michael C Heinrich, Janice Patterson, Carol Beadling, et al.
Cancer Cell|March 7, 2003
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classificationScott A Armstrong, Andrew L Kung, Meghann E Mabon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumorsJayesh Desai, Sridhar Shankar, Michael C Heinrich, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 13, 2016
Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell lineYvonne de Jong, Annemiek M van Maldegem, Adrian Marino-Enriquez, et al.
Annals of Surgical Oncology|May 17, 2012
Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk markerChueh-Chuan Yen, Chun-Nan Yeh, Chi-Tung Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2006
Molecular correlates of imatinib resistance in gastrointestinal stromal tumorsMichael C Heinrich, Christopher L Corless, Charles D Blanke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Midline carcinoma of children and young adults with NUT rearrangementChristopher A French, Jeffery L Kutok, William C Faquin, et al.
Pageof 21

Showing results (141-150 of 205) with videos related to

Sort By:
Pageof 21
The American Journal of Surgical Pathology|March 30, 2012
The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumorCheng-Han Lee, Adrian Mariño-Enriquez, Wenbin Ou, et al.
British Journal of Cancer|May 4, 2016
Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapyMarieke A de Graaff, Marije A J de Rooij, Brendy E W M van den Akker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2006
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)Michael C Heinrich, Grant A McArthur, George D Demetri, et al.
Clinical Sarcoma Research|March 15, 2019
Genomic aberrations in cell cycle genes predict progression of <i>KIT</i>-mutant gastrointestinal stromal tumors (GISTs)Michael C Heinrich, Janice Patterson, Carol Beadling, et al.
Cancer Cell|March 7, 2003
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classificationScott A Armstrong, Andrew L Kung, Meghann E Mabon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumorsJayesh Desai, Sridhar Shankar, Michael C Heinrich, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 13, 2016
Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell lineYvonne de Jong, Annemiek M van Maldegem, Adrian Marino-Enriquez, et al.
Annals of Surgical Oncology|May 17, 2012
Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk markerChueh-Chuan Yen, Chun-Nan Yeh, Chi-Tung Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2006
Molecular correlates of imatinib resistance in gastrointestinal stromal tumorsMichael C Heinrich, Christopher L Corless, Charles D Blanke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Midline carcinoma of children and young adults with NUT rearrangementChristopher A French, Jeffery L Kutok, William C Faquin, et al.
Pageof 21